Caplin Steriles Gains USFDA Approval for Potassium Phosphates Injection

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Ltd, has secured final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Potassium Phosphates Injection USP. This injection is a generic therapeutic equivalent of the Reference Listed Drug from Fresenius Kabi USA, LLC. The product is available in 5 mL, 15 mL, and 50 mL vials, containing phosphorus 3 mmol/mL and potassium 4.4 mEq/mL.

The financial data indicates that the Potassium Phosphates Injection USP had US sales of approximately $57 million for the 12-month period ending January 2026. This figure is sourced from IQVIATM (IMS Health). The approval allows Caplin Steriles to enter this market with its generic version, potentially capturing a share of these sales.

The scope of the approval covers the use of Potassium Phosphates Injection as a source of phosphorus in intravenous fluids. It is utilized to correct hypophosphatemia and is also used as parenteral nutrition in both adult and pediatric patients who are unable to take oral supplements. The injection is designed to meet the therapeutic needs of patients requiring phosphorus supplementation through intravenous administration.

Caplin Steriles Limited has developed and filed 54 ANDAs in the United States, with 53 approvals to date, including acquired ANDAs. The company is also working on a portfolio of over 55 injectable and ophthalmic products intended for filing over the next four years. Additionally, Caplin Steriles has multiple products filed and approved in non-US markets, including Australia, Canada, Mexico, and several others.

The timeline for the implementation of this approval is immediate, as the USFDA has granted final approval. Caplin Steriles Limited, as the involved entity, will manage the production and distribution of the Potassium Phosphates Injection USP in the US market.

Caplin Point Laboratories Ltd is a pharmaceutical company focusing on emerging markets in Latin America and Africa. The company operates state-of-the-art manufacturing facilities and has been recognized for consistent growth in cash flows, profitability, and revenues over the past 15 years. Caplin Point has appeared on Forbes “Asia’s 200 Best Under a Billion” list multiple times and has received awards for business excellence.